ECE2015 Eposter Presentations Diabetes (complications & therapy) (143 abstracts)
Male patients benefit from initial exenatide treatment: a real-world experience
Liang Chen , Jian Kuang , Jianhao Pei , Hongmei Chen , Zhong Chen , Zhongwen Li , Huazhang Yang , Xiaoyin Fu , Long Wang & Zhijiang Chen
The First Division of Endocrinology, Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangzhou City, China.
Objective: The purpose of this study was to describe the outcome after initiation of exenatide therapy and to determine whether the impact of adverse drug reactions on compliance was affected by gender.
Methods: A retrospective study was performed of 18 diabetic patients (eight males) that were prescribed exenatide between June 2013 and September 2014. Each included patient received exenatide for ≥1 month. Age, disease course, race, BMI, medical history, chronic complications associated with diabetes, and the state of pretreatment glycaemic control were analyzed. Both 1 and 4 weeks after treatment, data such as blood glucose, blood lipids, and body weight were collected to determine any adverse drug reactions and the impact of gender on exenatide withdrawal.
Results: The incidence of adverse drug reaction was significantly higher in female than male patients following exenatide treatment (P<0.05). Although there was no significant difference between the male and female group 1 week, adverse drug reactions continued longer in females and the incidence of adverse drug reaction was significantly higher in female patients 4 weeks after initiating treatment (P<0.01). As a result, four female patients stopped taking the medication, whereas only one male patient stopped taking the medication because the patient was unaccustomed to the drug injection process. The efficacy of exenatide was similar between the two groups at both 1 and 4 weeks.
Conclusion: Exenatide, a glucagon-like peptide 1 agonist often causes relatively significant gastrointestinal reactions during its initial application. Gender difference in adverse drug reactions may be due to the impact of this drug on the feeding centre in the CNS.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more